Press Releases September 1, 2026 07:00 AM

Harrow to Participate in Three Investor Conferences in September

Harrow to Present at Three Major Investor Conferences in September 2026

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
HROW

Harrow, Inc., a Nasdaq-listed North American ophthalmic disease management company, announced its management participation in three investor conferences in New York City during September 2026, featuring fireside chats and one-on-one investor meetings. The events aim to provide updates on company strategy and market presence.

Harrow to Participate in Three Investor Conferences in September
HROW
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Harrow will participate in the 2026 Cantor Global Healthcare Conference, Lake Street Capital Markets 10th Annual Best Ideas Growth Conference, and the H.C. Wainwright 28th Annual Global Investment Conference.
  • The presentations include fireside chats and private investor meetings, offering insights into Harrow's ophthalmic product portfolio and corporate direction.
  • Webcasts of the fireside chats will be available live and for 90 days afterwards, enhancing investor accessibility.

NASHVILLE, Tenn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following three investor conferences in September in New York, NY:

2026 Cantor Global Healthcare Conference

  • Format: Fireside chat + 1x1 investor meetings
  • Date/Time: Wednesday, September 9, 2026, at 1:35 p.m. ET

Lake Street Capital Markets 10th Annual Best Ideas Growth Conference

  • Format: 1x1 investor meetings
  • Date/Time: Thursday, September 10, 2026

H.C. Wainwright 28th Annual Global Investment Conference

  • Format: Fireside chat + 1x1 investor meetings
  • Date/Time: Tuesday, September 15, 2026, at 11:00 a.m. ET

The fireside chats at Cantor and H.C. Wainwright will be webcast live and can be accessed on the Events page of the Company’s website. A replay of each webcast will be available for approximately 90 days following the applicable event. Investors interested in meeting with management during any of these conferences should contact their representative at the sponsoring firm to request a meeting.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and diseases of the retina. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.

Contacts:
Mike Biega
Vice President of Investor Relations and Communications
[email protected]
617-913-8890


Risks

  • The company’s market reactions depend heavily on effective communication and investor perceptions at these events, which carry inherent uncertainties.
  • Success in competitive ophthalmic pharmaceutical markets is uncertain amid evolving healthcare regulations and product adoption rates.
  • Dependence on North American markets may expose Harrow to regional economic and healthcare policy risks.

More from Press Releases

Zhihu Inc. Announces Proposed Subscription in AI-Focused Investment Fund Sep 6, 2026 Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call Sep 6, 2026 Verizon Waives Charges for Hurricane Lowell, Prepares Network in Hawai'i Sep 5, 2026 Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen Sep 4, 2026 Grupo Aeroportuario del Pacifico Reports a Passenger Traffic Increase in August 2026 of 0.5% Compared to 2025 Sep 4, 2026